
IonSense has appointed Jeffrey Zonderman as President and Chief Executive Officer. Mr Zonderman brings experience gained from commercialising disruptive technologies at early-stage ventures including RedShift Bioanalytics and Cohesive Technologies, as well as major instrument manufacturers including Thermo Fisher Scientific and Waters Corporation.
“We are thrilled Jeff has joined IonSense as his experience positions him well to lead the company and achieve our strategic vision”, said Bob Linke, Executive Chairman of the Board. “I’d also like to thank Dr Brian Musselman whose contributions in founding and leading the company to establish the DART technology in labs around the world have been tremendous. We are pleased to announce Dr Musselman will take on the newly created role as IonSense’s Chief Technology Officer to guide proprietary DART technology through its next stage of growth outside the central lab. Brian’s vision will continue to play a key role developing IonSense’s technologies to achieve our strategic goals.”




![Targeted proton transfer charge reduction (tPTCR) nano-DESI mass spectrometry imaging of liver tissue from orally dosed rat (Animal 3). a) optical image of a blood vessel within liver tissue. b) Composite ion image of charge-reduced haeme-bound α-globin (7+ and 6+ charge states; m/z 2259.9 and m/z 2636.3 respectively, red) and the charged-reduced [FABP+bezafibrate] complex (7+ and 6+ charge states; m/z 2097.5 and m/z 2446.9 respectively, blue). c) Ion image composed from charge-reduced haeme-bound α-globin (7+ and 6+ charge states) showing abundance in blood vessels. d) Ion image composed from charge-reduced [FABP+bezafibrate] complex (7+ and 6+ charge states) showing abundance in bulk tissue and absence in the blood vessel. Reproduced from https://doi.org/10.1002/ange.202202075 under a CC BY licence. Light and mass spectromert imaging of tissue samples](/sites/default/files/styles/thumbnail/public/news/MSI%20drug-protein%20complex-w.jpg?itok=CBNIjyYl)




